MET inhibition in lung cancer Full Text
Translational Lung Cancer Research,  Review Article

Menis J. et al .– This paper aims to summarize data on Met biological function, on its interaction with cell signaling and other pathways and to present data on those Met inhibitors currently under evaluation. The discovery of new cancer–driver genes and the enforcement of molecules targeting them have changed the landscape of Non Small Cell Lung Cancer (NSCLC) treatment.As a matter of fact, the previous scenario of advanced NSCLC treatment has been completely revolutionized, switching from a “one size fits all” approach to a personalized therapy. It was concluded that Met can act as an ‘oncogene expedient’ even in absence of genetic alterations and might potentiate the effect of other oncogenes, promote malignant progression and participate in tumor angiogenesis. Met dysregulation correlates with disease prognosis in numerous cancers and represents a possible target for personalized treatment. The clinical efficacy of Met targeting agents in lung cancer needs further details from the ongoing trials as well as more information are necessary to establish the most appropriate diagnostic test to identify Met expression or amplification.

  • Met is a heterodimer receptor tyrosine kinase composed of a ?–chain and a ?–chain, linked by a disulphide bond.
  • Met was originally isolated as the product of a human oncogene, trp–met, in tumor cells treated with a chemical carcinogen.
  • Met gene encodes a 170–kD protein (p170met) that has constitutive and ligand–independent tyrosin–kinase activity.
  • Met has pivotal functions in embryogenesis and organogenesis of placenta, liver, kidney, neurons and muscles.
  • Moreover, in vivo, Met receptor activation determines a phenomenon called “invasive growth”, which includes cell proliferation, scattering, survival, motility and invasion, epithelial–mesenchymal transition and branched morphogenesis
  • In this scenario Met, a heterodimere receptor tyrosine kinase deeply involved into embryogenesis and organogenesis, has been introduced many years ago as a potential target for biological agents, becoming“druggable” only in this last period of time.
  • Met can be altered through receptor overexpression, genomic amplification, mutations or alternative splicing, autocrine or paracrine secretion of hepatic growth factor (HGF): these dysregulations stimulate tumorigenesis (in terms of cell–cell detachment, proliferation, invasion, angiogenesis and survival) and metastatization.
  • Met is overexpressed in lung cancer and Met gene amplification can drive the dependency of cell survival and proliferation upon the Met signaling. Both Met overexpression and amplification seem to correlate with poor prognosis.
  • Met amplification is also described to be linked to EGFR acquired resistance.
  • Several Met inhibitors have been tested both in preclinical and human trials, demonstrating activity in lung cancer treatment.
  • In patients with advanced NSCLC, a correct definition of the histotype is still the first step to design a proper therapeutic algorithm, but personalized molecular diagnosis is becoming more and more relevant.
  • Several molecules are currently under investigation and two of them already reached phase III trials in advanced NSCLC.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

2 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response The Lancet Oncology, August 19, 2014    Clinical Article

3 Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies Breast Cancer Research and Treatment, August 1, 2014    Evidence Based Medicine    Review Article

4 Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany The Breast, July 24, 2014

5 Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer International Journal of Cancer, August 11, 2014    Clinical Article

6 A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia British Journal of Haematology, August 11, 2014    Clinical Article

7 Observation after a positive sentinel lymph node biopsy in patients with melanoma Annals of Surgical Oncology, August 20, 2014    Clinical Article

8 Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study Journal of Clinical Oncology, July 17, 2014

9 Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: A population-based analysis Full Text BMC Cancer, August 21, 2014    Free full text    Clinical Article

10 A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study Journal of Cancer Research & Clinical Oncology, August 29, 2014    Clinical Article

11 Screening for prostate cancer in the US? Reduce the harms and keep the benefit International Journal of Cancer, August 15, 2014    Clinical Article

12 Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group study, N0675 American Journal of Clinical Oncology, August 14, 2014    Clinical Article

13 Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer Breast Cancer Research and Treatment, August 4, 2014    Clinical Article

14 FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial The Lancet Oncology, August 4, 2014    Clinical Article

15 Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: The Cancer Prevention Study-II Nutrition Cohort Journal of Clinical Oncology, July 9, 2014    Clinical Article

16 Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology, March 7, 2014    Clinical Article

17 Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR Breast Cancer Research and Treatment, August 12, 2014    Clinical Article

18 Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012 empirical relationships JAMA Dermatology, August 13, 2014    Review Article

19 Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells Cancer, July 2, 2014    Clinical Article

20 Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma Full Text BMC Cancer, August 1, 2014    Free full text

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close